Loading news...
Vericel Corporation (NASDAQ: VCEL - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among
Vericel Corporation (VCEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Total Revenue Expected to be $276 Million MACI Revenue Expected to be $239.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% CAMBRIDGE, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary, unaudited financial results and other business updates for the fourth quarter and year ended December 31, 2025.
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference at 2:15 p.m. ET (11:15 a.m. PT) on Wednesday, January 14, 2026.
Vericel Corporation (NASDAQ: VCEL - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price
Frontier Capital Management Co. LLC increased its holdings in Vericel Corporation (NASDAQ: VCEL) by 74.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 398,960 shares of the biotechnology company's stock after buying an additional 170,006 shares during the period. Frontier Capital
Vericel Corporation (NASDAQ: VCEL - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Stephens Annual Investment Conference at 11:00 a.m. ET (10:00 a.m. CT) on Thursday, November 20, 2025.
The average of price targets set by Wall Street analysts indicates a potential upside of 39.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Vericel Corporation ( VCEL ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Eric Burns - Vice President of Finance & Investor Relations Dominick C. Colangelo - CEO, President & Director Joseph Mara - CFO & Treasurer Conference Call Participants Joshua Jennings - TD Cowen, Research Division Richard Newitter - Truist Securities, Inc., Research Division Ryan Zimmerman - BTIG, LLC, Research Division Caitlin Roberts - Canaccord Genuity Corp., Research Division Michael Kratky - Leerink Partners LLC, Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good day, and welcome to the Vericel Corporation Third Quarter 2025 Earnings Call.
Baltimore-based Brown Capital Management sold 861,020 shares of Vericel Corporation in the third quarter for an estimated $31 million. The transaction value represented 1.3% of Brown Capital's 13F reportable AUM as of quarter-end.
Vericel Corporation (VCEL) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.02 per share a year ago.
Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating Cash Flow of $22.1 Million More than 800 MACI Arthro Surgeons Trained to Date Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2025.
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Wells Fargo Healthcare Conference at 3:45 p.m. ET on Thursday, September 4, 2025.
Vericel Q2 Revenue Jumps 20%
Vericel Corporation (VCEL) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.1 per share a year ago.
Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million, with Adjusted EBITDA Margin Increase of More than 900 Basis Points to 21% Approximately 600 MACI Arthro Surgeons Trained to Date Received FDA IND Clearance for Phase 3 MACI Ankle Clinical Study Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2025.
CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second-quarter 2025 financial results on Thursday, July 31, 2025. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.
Vericel's valuation has moderated after a 20% share price drop, prompting a shift from sell to neutral. MACI remains the company's primary growth engine, with strong sales momentum and successful surgeon training on new indications. The stock enjoys bullish analyst firm support and Vericel's balance sheet is in a strong position.
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Truist Securities MedTech Conference at 9:20 a.m. ET on Tuesday, June 17 2025.